Impact of prophylactic pyridoxine on occurrence of hand-foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer

Breast Cancer

Volumn 17, Issue 4, 2010, Pages 298-302

  Yoshimoto, Nobuyasu ^a   Yamashita, Toshinari ^a   Fujita, Takashi ^a   Hayashi, Hironori ^a   Tsunoda, Nobuyuki ^a   Kimura, Mariko ^a   Tsuzuki, Norimasa ^a   Yamashita, Hiroko ^b   Toyama, Tatsuya ^b   Kondo, Naoto ^b   Iwata, Hiroji ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b NAGOYA CITY UNIVERSITY   (Japan)

Author keywords

Capecitabine; Hand foot syndrome; Pyridoxine prophylaxis; Urea ointment

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; CYCLOPHOSPHAMIDE; EPIRUBICIN; PYRIDOXINE; TAXANE DERIVATIVE; UREA;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PATIENT; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG RESPONSE; DRUG SAFETY; HAND FOOT SYNDROME; HUMAN; METASTASIS; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RISK REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; BREAST NEOPLASMS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; FOOT DERMATOSES; HAND DERMATOSES; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; PYRIDOXINE; RETROSPECTIVE STUDIES; VITAMIN B COMPLEX;

EID: 77958102023     PISSN: 13406868     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12282-009-0171-3     Document Type: Article

References (24)

1. M Miwa M Ura M Nishida N Sawada T Ishikawa K Mori, et al. 1998 Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue Eur J Cancer 34 1274 1281 1:CAS:528:DyaK1cXltlCgsrk%3D 10.1016/S0959-8049(98)00058-6 9849491 (Pubitemid 28342121)
2. JL Blum SE Jones AU Buzdar PM LoRusso I Kuter C Vogel, et al. 1999 Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer J Clin Oncol 17 485 493 1:CAS:528:DyaK1MXht1Wmurw%3D 10080589
3. JL Blum V Dieras PM LoRusso J Horton O Rutnan A Buzdar, et al. 2001 Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients Cancer 92 1759 1768 1:CAS:528:DC%2BD3MXosV2qsLw%3D 10.1002/1097-0142(20011001)92:7<1759::AID-CNCR1691>3.0.CO;2-A 11745247 (Pubitemid 32952493)
4. P Fumoleau R Largillier C Clippe V Dièras H Orfeuvre T Lesimple, et al. 2004 Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer Eur J Cancer 40 536 542 1:CAS:528:DC%2BD2cXhtFWjsbc%3D 10.1016/j.ejca.2003.11.007 14962720 (Pubitemid 38220770)
5. P Reichardt G von Minckwitz PC Thuss-Patience W Jonat H Kölbl F Jänicke, et al. 2003 Multicenter phase II study of oral capecitabine (Xeloda) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy Ann Oncol 14 1227 1233 1:STN:280: DC%2BD3szkvVaruw%3D%3D 10.1093/annonc/mdg346 12881384 (Pubitemid 37039048)
6. JJ Lokich C Moore 1984 Chemotherapy-associated palmar-plantar erythrodysethesia syndrome Ann Intern Med 101 798 800 1:STN:280: DyaL2M%2FksFWnsQ%3D%3D 6497196
7. W Scheithauer J Blum 2004 Coming to grips with hand-foot syndrome. Insights from clinical trials evaluating capecitabine Oncology 18 1161 1168 15471200
8. D Rossi G Catalano 2007 Pyridoxine as prophylactic therapy for palmar-plantar erythrodysesthesia associated with administration of pegylated liposomal doxorubicin (Caelyx): a single-center experience Oncology 73 277 278 1:STN:280:DC%2BD1c3ot1Kksg%3D%3D 10.1159/000127427 18424894 (Pubitemid 351630062)
9. ME Lacouture S Wu C Robert MB Atkins HH Kong J Guitart, et al. 2008 Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib Oncologist 13 1001 1011 1:CAS:528:DC%2BD1cXhtlaksrrP 10.1634/theoncologist.2008-0131 18779536
10. E Bajetta G Procopio L Celio L Gattinoni SD Torre L Mariani, et al. 2005 Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women J Clin Oncol 23 2155 2161 1:CAS:528:DC%2BD2MXjsVyiu78%3D 10.1200/JCO.2005.02.167 15710946 (Pubitemid 46218707)
11. L El-Helw RE Coleman 2005 Reduced dose capecitabine is an effective and well-tolerated treatment in patients with metastatic breast cancer Breast 14 368 374 1:STN:280:DC%2BD2MrktVKltw%3D%3D 10.1016/j.breast.2004.12.005 16216738 (Pubitemid 41510193)
12. M Stockler T Sourjina P Grimison V Gebski M Byrne V Harvey, et al. 2007 A randomized trial of capecitabine (C) given intermittently (IC) rather than continuously (CC) compared to classical CMF as first-line chemotherapy for advanced breast cancer (ABC) J Clin Oncol 25 1031
13. JE Mortimer MK Lauman B Tan CL Dempsey AC Shillington KS Hutchins 2003 Pyridoxine treatment and prevention of hand-and-foot syndrome in patients receiving capecitabine J Oncol Pharm Practice 9 161 166 1:CAS:528: DC%2BD3sXhtVSru7jI 10.1191/1078155203jp116oa (Pubitemid 37461547)
14. SM Gressett BL Stanford F Hardwicke 2006 Management of hand-foot syndrome induced by capecitabine J Oncol Pharm Practice 12 131 141 1:CAS:528: DC%2BD28XhtlSksrfL 10.1177/1078155206069242 (Pubitemid 44696441)
15. CJ Fabian R Molina M Slavik S Dahlberg S Giri R Stephen 1990 Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion Invest New Drugs 8 57 63 1:STN:280:DyaK3c3msVWntw%3D%3D 10.1007/BF00216925 2345070
16. JE Mortimer I Anderson 1990 Weekly fluorouracil and high dose leucovorin: efficacy and treatment of cutaneous toxicity Cancer Chemother Pharmacol 26 449 452 1:STN:280:DyaK3M%2FivFyiuw%3D%3D 10.1007/BF02994097 2225317
17. S Lee S Lee Y Chun M Kim H Chang T Kim, et al. 2007 Pyridoxine is not effective for the prevention of hand foot syndrome (HFS) associated with capecitabine therapy; results of a randomized double-blind placebo-controlled study J Clin Oncol 25 9007
18. D Pendharkar H Goyal 2004 Novel & effective management of capecitabine induced hand foot syndrome J Clin Oncol 22 8105
19. M Kurt S Aksoy N Guler 2006 Could the hand-foot syndrome after capacitabine treatment be associated with better outcome in metastatic breast cancer patients? Acta Oncol 45 625 626 10.1080/02841860600791509 16864181 (Pubitemid 44167218)
20. Twelves C, Scheithauer W, McKendrick J, Nowacki M, Seitz J, Van Hazel G, et al. Capecitabine versus 5.FU/LV in stage III colon cancer: updated 5-year efficacy data from X-ACT trial and preliminary analysis of relationship between hand-foot syndrome (HFS) and efficacy. Gastrointest Cancers Symp. 2008 (Abstract #274).
21. C Jack S Ivana C David F Lesley 2008 Treatment-emergent endocrine symptoms and risk of breast cancer recurrence: a retrospective analysis of the ATAC trial Lancet Oncol 9 1143 1148 10.1016/S1470-2045(08)70259-6
22. G Milano MC Etienne-Grimaldi M Mari S Lassalle JL Formento M Francoual, et al. 2008 Candidate mechanisms for capecitabine-related hand-foot syndrome Br J Clin Pharmacol 66 88 95 1:CAS:528:DC%2BD1cXptVKis78%3D 10.1111/j.1365-2125. 2008.03159.x 18341672 (Pubitemid 351822156)
23. MW Saif V Juneja G Black J Thronton MR Johnson RB Diasio 2007 Palmar-plantar erythrodysesthesia in patients receiving capecitabine and intratumor thymidine phosphorylase and dihydropyrimidine dehydrogenase: is there a pharmacologic explanation? Supportive Cancer Ther 4 211 218 1:CAS:528:DC%2BD2sXht1emtLzL 10.3816/SCT.2007.n.017
24. J Honda M Sasa T Moriya Y Bando T Hirose M Takahashi, et al. 2008 Thymidine phosphorylase and dihydropyrimidine dehydrogenase are predictive factors of therapeutic efficacy of capecitabine monotherapy for breast cancer-preliminary results J Med Invest 55 54 60 10.2152/jmi.55.54 18319546 (Pubitemid 351643594)